Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Pharmacogenomics in autism treatment  

Risperidone, the most studied atypical antipsychotic used in children, has been shown to improve severe behavioral symptoms in over half of children with autism with these problems. However, not all children with autism and severe behavioral problems respond to risperidone, and for a few, it has significant side effects. Blood genomic profiles are shown to predict medication response for disorders such as cancer and epilepsy. This study proposes to use blood genomic profiles before and after risperidone treatment in children with autism and severe behavioral problems to determine if the profiles can predict response to treatment. The ultimate goal of this line of research is to develop methods to predict which medications work for which child before initiating treatment, to predict which child might develop particular side effects, and to identify new treatment targets for future medication development.


Funder National Institutes of Health
Fiscal Year Funding $171,000.00
Project Number R21MH080026-01A1
Principal Investigator Hendren, Robert
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective 4O. Not specific to Question 4 objectives
Federal or Private? Federal
Institution University of California, Davis
State/Country California
Web Link 1 No URL available.
Web Link 2 No URL available.
Web Link 3 No URL available.
History/Related Projects Pharmacogenomics in autism treatment | $83,961.00 | 2009 | 5R21MH080026-02
Pharmacogenomics in autism treatment | $121,239.00 | 2009 | 7R21MH080026-03